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Available online xxxxMucopolysaccharidosis (MPS) VI is an autosomal recessive lysosomal storage disorder arising from deﬁcient ac-
tivity of N-acetylgalactosamine-4-sulfatase (arylsulfatase B) and subsequent intracellular accumulation of the
glycosaminoglycans (GAGs) dermatan sulfate and chondroitin-4-sulfate. Manifestations are multi-systemic
and include skeletal abnormalities such as dysostosis multiplex and short stature. Reference height-for-age
growth charts for treatment-naïve MPS VI patients have been published for both the slowly and rapidly
progressing populations. Categorization of disease progression for these charts was based on urinary GAG
(uGAG) level; high (N200 μg/mg creatinine) levels identiﬁed subjects as rapidly progressing. Height data for
141 patients who began galsulfase treatment by the age of 18 years were collected and stratiﬁed by baseline
uGAG level and age at ERT initiation in 3-year increments. The reference MPS VI growth charts were used to cal-
culate change in Z-score from pre-treatment baseline to last follow-up. Among patients with high baseline uGAG
levels, galsulfase ERTwas associated with an increase in Z-score for those beginning treatment at 0–3, N3–6, N6–
9, N9–12, and N12–15 years of age (p b 0.05). Increases in Z-scorewere not detected for patientswhobegan treat-
ment between 15 and 18 years of age, nor for patients with low (≤200 μg/mg creatinine) baseline uGAG levels,
regardless of age at treatment initiation. The largest positive deviation from untreated reference populations
was seen in the high uGAG excretion groups who began treatment by 6 years of age, suggesting an age- and se-
verity-dependent impact of galsulfase ERT on growth.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Galsulfase1. Introduction
Mucopolysaccharidosis VI (MPS VI, or Maroteaux-Lamy syndrome;
OMIM 253200) is a rare autosomal recessive genetic disorder caused
by a deﬁciency in N-acetylgalactosamine-4-sulfatase (arylsulfatase B
(ASB); E.C.3.1.6.1), which results in intracellular accumulation of the en-
zyme substrate, the glycosaminoglycans (GAGs) dermatan sulfate and
chondroitin 4-sulfate. This progressive accumulation manifests asrs for Disease Control and
Glycosaminoglycans; MPS VI,
glycans.
. This is an open access article under
al., The effect of galsulfas
syndro..., Mol. Genet. Metab.clinically progressive disease with multi-systemic involvement [1].
Most patients with a rapidly progressing course show classical MPS VI
symptoms by age 2 to 3 years, including short stature, joint and skeletal
abnormalities, and spinal cord compression. Other manifestations in-
clude corneal opaciﬁcation, respiratory insufﬁciency and impaired en-
durance, and cardiac valve stenosis and/or regurgitation [1]. Patients
with a slower progression may not necessarily present with short stat-
ure and can sometimes reach adult heights that are comparable to unaf-
fected (non-MPS VI) peers; however, these patients also experience
signiﬁcant morbidity by their teenage years or later, including skeletal
complications, cardiac valve abnormalities, and reduced endurance [2].
Growth in height in MPS VI patients starts to falter by age 2 to
3 years. The degree of deceleration is greater in patients with high
(N200 μg/mg creatinine) urinary GAG (uGAG) levels compared tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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height percentile growth charts up to 18 years of age were developed
for both rapidly and slowly progressing populations [4]. Due to limited
differences in growth between male and female MPS VI patients, these
charts are not gender-speciﬁc [4]. Growth stops around 12 years of
age for patients with high uGAG levels; mean adult height is approxi-
mately 110 cm. Conversely, patients with low uGAG levels continue
growing into their teenage years with a mean adult height of 145 cm.
Growth charts for these two patient populations provide a useful tool
for monitoring height attainment inMPS VI children and allow tracking
of the effect of therapeutic interventions on growth.
MPS VI clinical trials have shown that enzyme replacement therapy
(ERT) with galsulfase (recombinant human (rh) ASB; Naglazyme®,
BioMarin Pharmaceutical Inc., Novato, CA) is effective in improving en-
durance and pulmonary function, reducing intracellular GAG accumula-
tion, and stabilizing cardiac manifestations [5,6,7]. In a cohort of
patients, some of whom were included in the current study, a 10-year
follow-up study [8] and longitudinal modeling of pooled data from clin-
ical trials [9] indicated a long-term beneﬁcial effect of galsulfase ERT on
endurance, respiratory function, and growth rates. Reference growth
charts for MPS VI were not available at the time for comparison of treat-
ed and treatment-naïve populations, but have since been developed [4].
The objective of the current study was to evaluate the impact of
galsulfase ERT on growth using the recently developed height-for-age
reference charts for untreated MPS VI patients.
2. Methods
2.1. Patient population and data collection
Serial height-for-age data for MPS VI patients were obtained from
assessments collected during patient participation in the galsulfase clin-
ical trials (NCT00299000, NCT00048620, NCT00048711, NCT00067470,
NCT00104234), a cross-sectional survey study [3], a 10-year follow-up
resurvey study (NCT01387854) [8], and theMPS VI clinical surveillance
program (NCT00214773). Each patient was assigned a unique identiﬁ-
cation number and data were pooled from all studies at a per patient
level to avoid redundancies for patients who had enrolled in more
than one study. Patients who had baseline uGAG and height data avail-
able, began ERT by 18 years of age, and reported at least one post-ERT
height measurement were included in the analysis. Height measure-
ments had to be obtained before or within one month after galsulfase
ERT initiation to be considered baseline values. None of the evaluated
patients had undergone a hematopoietic stem cell transplant. For as-
sessments performed under 2 years of age, reported height measure-
ments likely represent length, the accepted method for assessment in
this age group. The MPS VI standard growth curves do not extend
below 2 years of age because of insufﬁcient data [4]; however, patients
under 2 years of age appear to differ very little in growth in length from
the unaffected population (unpublished data). Therefore, U.S. Centers
for Disease Control and Prevention (CDC) b2 years length-for-age data
were used as a reference [10] for length and Z-score calculations for
MPS VI patients under 2 years of age. Because the MPS VI growth charts
are not sex-speciﬁc, CDCmale and female length values were averaged.
2.2. Patient classiﬁcation
Pre-treatment uGAG levels were quantiﬁed from the ﬁrst voided
morning sample by spectrophotometric detection of metachromatic
change in the 1,9-dimethyl-methylene blue dye upon GAG bindingFig. 1.Height-for-age plots of galsulfase-treatedMPS VI patients. Height measurements of MPS
blue (pre-galsulfase ERT) and red (post-galsulfase ERT initiation). Pre-galsulfase ERT uGAG va
respectively. Rapidly (a, c, e, g, i, k) and slowly (b, d, f, h, j, l) progressing patient data are sho
d), N6–9 (e, f), N9–12 (g, h), N12–15 (i, j), and N15–18 years (k, l). Reference curves (black)
and the average of US CDC male and female length charts (age 0–2 years, dotted line).
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cal Inc. (Boston, MA) or BioMarin Pharmaceutical Inc. (Novato, CA).
Values from each laboratory were in general alignment with each
other; however, it was not possible to generate a direct correlation or
conversion factor to equate results from one lab exactly with that of an-
other, as has been reported as typical for this method of measuring
uGAG [12]. If more than one pre-treatment uGAG value was available,
the average was used. Patients with high uGAG levels were classiﬁed
as rapidly progressing; patients with low uGAG levels were classiﬁed
as slowly progressing.2.3. Galsulfase treatment
All but ﬁve patients received galsulfase (Naglazyme®, BioMarin
Pharmaceutical Inc., Novato, CA) infusions at 1 mg/kgweekly according
to the prescribing information [13] and recommended standard of care
[14]. Of the remaining ﬁve patients, three received 0.2mg/kg during the
Phase 1/2 clinical trial (NCT00048620) [15] and two received 2mg/kg in
a Phase 4 study (NCT00299000) [7,16]. All ﬁve patients subsequently
received the 1 mg/kg/week dose.2.4. Statistical methods
Height-for-age measurements were plotted together with the pub-
lished 50th percentile reference curve for untreated rapidly or slowly
progressing MPS VI patients [4]. Height Z-scores were generated sepa-
rately for the group of patients with high uGAG levels and those with
low uGAG and were based on the correspondingMPS VI reference pop-
ulation growth chart. Mean Z-score change from ﬁrst available pre-
treatment assessment to last follow-up was calculated with and with-
out stratiﬁcation by age at treatment initiation (0–3, N3–6, N6–9, N9–
12, N12–15, and N15–18 years). P-values for the change in Z-score
were derived from paired 2-sided t-tests. A Pearson correlation coefﬁ-
cientwas calculated to assess the relationship between age at treatment
initiation and change in Z-score.3. Results
As of February 2016, 141 patients who began treatment by 18 years
of age had the necessary height and uGAG data available to be included
in this analysis. The majority (68%) were classiﬁed as rapidly
progressing based on the 200 μg/mg creatinine uGAG cut off level.
Mean years of galsulfase exposure were 5.5, 6.3, 6.9, 5.4, 3.2, and 1.2
for those who started treatment at ages 0–3, N3–6, N6–9, N9–12, N12–
15, and N15–18 years, respectively. The gender ratio was 72 males to
69 females.
Patient height-for-age data, grouped by baseline uGAG level and age
at treatment initiation, are shown in Fig. 1. Table 1 lists results of the Z-
score analysis. Among patients with high baseline uGAG levels,
galsulfase ERT was associated with an increase in Z-score. A moderate
negative correlation (r =−0.41) between improvements in height Z-
score and age at treatment initiation was detected (Supplemental
Fig. 1). When patients were stratiﬁed by age at treatment initiation, a
signiﬁcant increase in Z-score was seen for those beginning treatment
at 0–3, N3–6, N6–9, N9–12, and N12–15 years of age (Fig. 2). Signiﬁcant
increases in Z-scorewere not seen for patientswhobegan treatment be-
tween 15 and 18 years of age, nor for patients with low baseline uGAG
levels, regardless of age at treatment initiation.VI patients, stratiﬁed by age at treatment initiation and baseline uGAG level, are shown in
lues of ≤200 or N200 μg/mg creatinine deﬁned patients as slowly or rapidly progressing,
wn in separate panels for those who started galsulfase ERT from ages 0–3 (a, b), N3–6 (c,
are the 50th percentiles of the MPS VI height growth charts (age 2–18 years, solid line)
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Table 1
Mean (SD) height Z-scores (relative to slowly-progressing or rapidly-progressing MPS VI
growth charts) of galsulfase ERT-treated patients.
Age at treatment
initiation (years)
Baseline
Z-score
Change in
Z-score at last follow-up
P-value
0–18
High uGAG (n = 96) 0.01 (0.9) 0.53 (0.6) b0.0001
Low uGAG (n = 45) 0.06 (1.1) −0.19 (0.7) 0.08
0–3
Higha uGAG (n = 15) 0.61 (0.8) 1.00 (0.8) 0.0002
Lowb uGAG (n = 4) 0.55 (1.8) 0.26 (1.2) 0.7
N3–6
High uGAG (n = 9) −0.45 (1.0) 1.09 (0.8) 0.004
Low uGAG (n = 16) 0.10 (1.1) −0.61 (0.8) 0.006
N6–9
High uGAG (n = 25) −0.11 (0.7) 0.49 (0.5) b0.0001
Low uGAG (n = 6) 0.18 (0.9) 0.07 (0.4) 0.7
N9–12
High uGAG (n = 23) 0.10 (1.1) 0.23 (0.4) 0.01
Low uGAG (n = 9) 0.25 (0.9) −0.17 (0.4) 0.2
N12–15
High uGAG (n = 16) 0.01 (1.0) 0.52 (0.6) 0.003
Low uGAG (n = 8) −0.32 (1.4) 0.24 (0.4) 0.2
N15–18
High uGAG (n = 8) −0.47 (0.6) 0.06 (0.2) 0.4
Low uGAG (n = 2) −0.86 (0.2) −0.29 (0.3) 0.4
a N200 μg/mg creatinine.
b ≤200 μg/mg creatinine.
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The availability of reference growth charts for theMPS VI population
[4] allowed us to study the effect of galsulfase ERT and age at treatment
initiation on growth in this patient group relative to expected growth
for untreated patients. We found that the effect of galsulfase ERT on
growth was dependent upon baseline uGAG levels and the magnitude
of the effectwas dependent upon age at treatment initiation. The largest
positive deviation fromuntreated reference populationswas seen in the
high uGAG excretion groups who began treatment by 6 years of age,
suggesting an age- and severity-dependent impact of galsulfase ERT
on growth.
Our ﬁndings suggest that early initiation of galsulfase ERT is impor-
tant to maximize growth potential. The ﬁnding of an age-dependent
beneﬁt of galsulfase ERT is consistent with previous studies [8,9,17,
18]. In particular, sibling studies in which one sibling begins therapy
at a much younger age than the other provide compelling evidence of
beneﬁts of early galsulfase ERT initiation [17,18]. Additionally, a 2-year
Brazilian study of MPS VI children undergoing galsulfase ERT startingFig. 2.Mean Z-score change by age group at ERT initiation for patients ≤ 18 years of age
with pre-ERT uGAG values N 200 μg/mg creatinine. Calculations are based on ﬁrst
baseline and last follow-up height measurements. Z-scores are relative to the 50th
percentile of the published reference growth chart for the rapidly progressing MPS VI
population [4]. Error bars represent standard error.
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creased their pre-treatment growth percentile (perWorld Health Orga-
nization reference charts) relative to unaffected individuals [19].
Whether the greater height gain also results in reduced morbidity and
increased survival [3,8] is an important topic for future investigation.
We found no positive effect on height gain in patients with low
uGAG levels and, for one group (those who began treatment at N3–
6 years of age), a statistically signiﬁcant decrease in Z-scorewas inexpli-
cably observed. Patients with low uGAG levels are typically classiﬁed as
having a more slowly progressing form of the disease and, in the ab-
sence of treatment, tend to be signiﬁcantly taller than patients with
high uGAG levels, though still exhibiting reduced stature relative to
theunaffected population.Ourﬁndings indicate that the positive impact
of galsulfase on height outcomes may be dependent upon pre-treat-
ment uGAG level, with more rapidly progressing individuals experienc-
ing greater beneﬁt.
Typically, patients with rapidly progressing disease experience
growth delay around 2 to 3 years of age [1], and the difference in height
between slowly and rapidly progressing patients increases after age 4 to
5 years [4]. Although the mechanism of growth failure in patients
experiencing a rapid disease progression is poorly understood, accumu-
lation of GAGs in the growth plates and joints that leads to chondrocyte
dysfunction, growth plate disorganization, and cytokine and inﬂamma-
tory responses may contribute [20,21,22]. Because the effect of
galsulfase ERT on height in this study was more substantial in patients
who started treatment by 6 years of age, prevention of GAG accumula-
tion in the growth plates may be a potential mechanism for improving
growth in rapidly progressing patients.
The role of the endocrine system in the growth failure of MPS VI is
not known, and investigations into these factors are limited [9]; howev-
er, MPS VI is characterized by delayed puberty and the absence of a pu-
bertal growth spurt [9]. The MPS VI reference growth charts also
showed no evidence of a pubertal growth spurt during the teen years,
either by gender or by disease progression [4]. Based on the current
data, galsulfase ERT treatment does not seem to induce a growth spurt
coincident with the resolution of delayed puberty reported previously
[9]; however, more longitudinal data are required. Growth during the
pubertal period was not addressed directly in this or the previous
growth chart study [4]. This gap suggests an avenue for further research,
particularly considering that in clinical trials, 42% (10/24) of patients
were identiﬁed as having delayed puberty onset or progression of pu-
berty [9] and that galsulfase ERT treatment led to completion of puberty
in six of these patients while the rest showed progression.
Based on the ﬁndings from the current study aswell as the previous-
ly mentioned evidence of age-dependent impacts of ERT from the liter-
ature, early diagnosis and prompt initiation of galsulfase ERT seem to be
of critical importance. However, diagnosis of MPS VI during the ﬁrst
year of life is currently challenging. In most patients, growth is normal
up to 2 years of age; accelerated growth during infancy has also been re-
ported [18,23,24]. In addition, uGAG levels are naturally high and creat-
inine levels low during infancy and the upper limit of normal for the
ratio is not well deﬁned [25,26,27]. Hence the use of uGAG as a screen-
ing biomarker during infancy is limited to experienced laboratories [28].
Mild dysmorphic features, frequent airway infections, umbilical hernias,
and orthopedic abnormalities including hip displacement and kyphosis
are frequently present and often play a critical role in developing clinical
suspicion of MPS VI. Demonstration of low ASB activity in leukocytes or
ﬁbroblasts or identiﬁcation of two pathogenic genetic mutations in the
ARSB gene is necessary to conﬁrm the diagnosis. Currently, newborn
screening for lysosomal storage diseases, including MPS VI, is in the
pilot stage, and comparatively simple dried blood spot–based assays
are under development [29,30,31,32].
The main limitation of this study is the small sample size in some of
the age groups, particularly for patients with low uGAG levels. Although
no impact of ERT on height was found for these slowly progressing pa-
tients, further study of a larger patient population over a longer period ise enzyme replacement therapy on the growth of patients with
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of exposure to galsulfase was substantially shorter for patients over
15 years of age at treatment initiation relative to the rest of the patients
studied. More timemay be required to detect the effect of treatment for
these patients. When interpreting the results of this study, the limita-
tions of the reference growth charts used as the basis for the analysis
must also be taken into consideration. The reference growth charts
were developed with data from a relatively small number of patients
(207). However, as these patients were frommultiple countries and re-
gions, and represented approximately 19% of the estimated worldwide
MPS VI population [4], they likely provided a reasonable representation
of the overall natural history of the disease. Both the development of the
original reference growth charts and the current study exemplify that
sufﬁcient data on an ultra-rare disease like MPS VI can only be obtained
through the joint efforts of many clinicians. On a country-by-country
basis these cumulative data could not have been collected. At the
same time, it demonstrates that continuous efforts remain needed to
obtain further supportive evidence in larger numbers ofMPS VI patients
over longer periods of time.
In conclusion, we observed that the effect of galsulfase ERT on the
growth of MPS VI patients relative to MPS VI reference growth charts
depends on age of treatment initiation and pre-treatment uGAG levels.
Patients with high baseline uGAG levels who started treatment by
15 years of age demonstrated a signiﬁcant increase in height Z-score rel-
ative to the untreated population. Overall, our ﬁndings indicate that
early diagnosis ofMPSVI enabling early initiation of galsulfase ERT is es-
sential for maximizing growth potential in children with MPS VI.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgme.2017.03.008.
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